Researchers at VCU Massey Comprehensive Cancer Center are leading an international study that advances the understanding of ...
When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for ...
Results support initiation of Phase 2b clinical trial of tonlamarsen in patients with acute severe hypertension SOUTH SAN FRANCISCO, Calif., & PRINCETON, N.J.-- (BUSINESS WIRE)--March 28, 2026-- ...
Researchers identify the hippocampus and microglia as the "tipping point" that determines if chronic pain leads to depression ...
FDA alignment achieved on pivotal study design supporting a planned Biologics License Application (BLA) submission -- 30-patient pivotal study initiated, evaluating seizure reduction and ...
SUZHOU, China and MÖLNDAL, Sweden, March 20, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange ...
Q4 2025 Earnings Call March 24, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman ...
Welcome to Brii Bio's 2025 Full Year Financial Results and Corporate Update Conference Call. Our annual result announcements can be found on the Investor Relations section of our company website.
T Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related ...
Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results